Vivek Subbiah, MD

@VivekSubbiah

Drug Development| Precision Oncology| Tissue-Agnostic Precision Medicine #Oncologist, #Phase1trials, #PrecisionMedicine. Tweets=My own.

Nashville, TN, USA

tinyurl.com/4279rtbe

Replies Reposts Media

Vivek Subbiah, MD
@VivekSubbiah
Aug 27
ChatGPT has given me glasses- apparently that’s the minimum requirement to look scholarly 🤓 Thanks for including me @BalazsHalmosMD @PTarantinoMD but where is my share of baklava ? @chadinabhan @PGrivasMDPhD
Balazs Halmos
@BalazsHalmosMD
Aug 25
Replying to @gachanta @PTarantinoMD and 5 others
How ChatGPT pictures “The Pitt”
Vivek Subbiah, MD
@VivekSubbiah
Aug 27
Applications for 2026 Young Investigator Awards Are Closing on September 10 - Conquer Cancer - OncoDaily
Applications for 2026 Young Investigator Awards Are Closing on September 10 - Conquer Cancer -...
From oncodaily.com
Vivek Subbiah, MD
@VivekSubbiah
Aug 26
⭐️Really loving the wording in the daraxonrasib FDA approval. Clear autonomy for physicians, centered on patient needs. 👉🏼“The approval is for the treatment of adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not
Vivek Subbiah, MD
@VivekSubbiah
Aug 26
🚨🚨🚨⭐️HUGE news & a MAJOR milestone in oncology‼️ 👉🏼The FDA just approved the first targeted therapy for metastatic pancreatic cancer a breakthrough in precision oncology and a landmark step in making the BIG KRAS officially druggable ( beyond KRAS K12C) ❗️ $RVMD 👉🏼A new era in
Vivek Subbiah, MD
@VivekSubbiah
Aug 26
Daraxonrasib is being branded as “Rasonque”. Sounds like a French perfume inspired by the switch‑II pocket. “Rasonque: Lock the switch‑II pocket down, quiet the effector binding, & let the MAPK pathway finally take a nap” @OncoAlert 🤔 cc @BalazsHalmosMD @chadinabhan
Adam Feuerstein ✡️
@adamfeuerstein
Aug 26
Rasonque is pronounced Raz-on-cue $RVMD
Vivek Subbiah, MD
@VivekSubbiah
Aug 26
F.D.A. Approves the Drug Daraxonrasib That’s Poised to Transform Pancreatic Cancer - The New York Times
F.D.A. Approves the Drug Daraxonrasib That’s Poised to Transform Pancreatic Cancer
From nytimes.com